reason report
ipr settlement add certainti tail underwrit multipl
bottom line wednesday even us patent trademark
offic uspto announc alexion mp
reach settlement agreement principl would like time
formal execut agreement termin inter
ipr alexion soliri institut septemb last year
potenti invalid soliriss patent could result
earli biosimilar launch patent
upheld previous incorpor probabl success
us soliri forecast earli biosimilar launch late base
wednesday ipr settlement postpon first biosimilar
launch increas us soliri forecast
base statu quo scenario without biosimilar eros
us soliri residu valu significantli smaller
averag annual sale versu
expect ultomiri convert major
soliri patient soliri share alxn total sale
declin updat us soliri
forecast higher higher
updat us total revenu forecast higher
consensu
believ delay biosimilar launch margin
impact soliri valuat ipr settlement expect
contribut bp alexion top-lin growth
bp total revenu estim
consensu higher
higher price target slightli increas
reiter outperform rate alexion stock
biosimilar phase data expect tent
approv like ipr settlement delay biosimilar launch
least year base analysi histor ftc
data averag delay-to-market time generic/biosimilar drug
year pay-for-delay time month longer
compensation-rel settlement detail settlement term
disclos like wont disclos view
delay-to-market time like longer year put
biosimilar launch earliest start phase studi
eculizumab biosimilar abp earli expect report
data base clinicaltri gov anticip abp
get tent fda approv besid abp
limit number candid us activ clinic
develop samsung bioepi phase dont expect
addit ipr challeng biosimilar manufactur next
averag dcf price-to-earnings
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm ep exclud option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
ipr settlement offer moder boost alexion top-lin
growth minim tail opportun due ultomiri
convers compar consensu assum durabl us
soliri sale forecast assum faster
ultomiri convers faster biosimilar eros us
soliri forecast start fall significantli y/i
decreas view ipr settlement doesnt
fundament chang long-term outlook alexion franchis
total revenu forecast remain larg unchang believ
better drug ultomiri conveni durabl
convert major soliri share biosimilar enter
price-to-earnings multipl recoveri underway despit recent resurg
alexion stock compani forward price-to-earnings remain lowest among
large-cap peer also rel histor multipl link
alexion franchis view like continu grow
remain rel stabl next year investor
discourag compani capit alloc strategi
led seri unimpress bd activ synageva
syntimmun portola recent year despit
believ compani today valuat remain highli
attract acquisit candid larg biopharma compani look
revenu diversif rare diseas exposur recent elliott
note link expect increasingli posit sentiment
continu elev stock price near futur
price target rate stock
outperform alexion lead compani develop commerci treatment
complement-medi diseas histor greater alexion revenu come
two rare diseas indic soliri recent approv soliri myasthenia
gravi neuromyel optica nmo on-going launch ultomiri alexion final
diversifi portfolio beyond soliri two core ahu pnh indic believ
alexion increas revenu complement franchis competit
threat soliri overst view given long safeti efficaci histori soliri
well alexion progress develop improv version ultomiri greater
potenc longer half-lif conveni dose beyond complement kanuma strensiq
continu grow steadili still believ two product could combin contribut
expect oper margin maintain
futur find alexion well posit grow ep doubl digit next five
price target base simpl averag three
approach believ reason basi valu stock today approach
simpl price earn multipl compar large-cap biopharma compani
growth adjust near-term earn multipl ratio
discount cash flow dcf use rel multipl similar growth compani
ep appli ep estim alexion give fair valu
stock use expect ep compound-annual-growth-rate alexion period
current averag ratio larg molecul large-cap biotech
give ep multipl discount multipl
compress alexion appli ep estim give fair valu
final dcf use termin growth rate post give current valu
averag three valuat methodolog pt
risk view outlook valuat alexion includ major chang price
reimburs coverag label soliri compani main product today risk
includ commerci develop disappoint recent launch product strensiq
kanuma well develop disappoint addit indic soliri
successor complement inhibitor product asset obtain recent acquisit
final brand gener competitor product soliri come market captur
greater share caus greater market price disrupt current expect futur
outlook valuat would undermin opportun better perform valu
expect includ stronger initi adopt recent launch new product
forecast success develop commerci new indic soliri
beyond neuromyel optica myasthenia gravi novel rare diseas medicin time
horizon forecast
brand
type event
event trial detail
date known
up/down
expect
bridg trial pnh indic
file japan regulatori approv
anticip close acquisit
initi phase
initi phase
initi phase portion phase studi investig add-
current standard-of-car therapi
initi phase trial japan pend regulatori feedback
initi phase trial add-on therapi soliri pnh
initi poc trial combin
initi phase studi waiha
initi phase studi gmg
svb leerink llc equiti research compani file
svb leerink llc equiti research compani file
begin phase
begin phase
phase data
data readout
select indic phase
begin phase
begin phase
begin phase japan
begin phase
phase top-lin data
initi phase renal studi
begin phase urgent surgeri
million
svb leerink llc research compani file
million
good sold
 total revenu
sg total revenu
svb leerink llc research compani file
analysi stock price svb leerink target alexion
multipl ep svb leerink estimate earn
current averag larg cap biopharma multipl ep
svb leerink adjust ep estim
capit
number period
impli target price
method leerink intrins valu base dcf current product net
current svb leerink dcf marketed/l stage program
current estim valu asset
method project forward earn multipl ep base ep
compound-annual-growth-rate larg cap biotech ratio
averag slow growth larg cap biotech co
impli ep multipl discount vs full growth-adj multipl
averag method
svb leerink llc research compani file factset
